Holen Sie sich die Stockscreener-App
16.00
2.50%
0.39
Handel nachbörslich:
16.10
0.10
+0.63%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.61
Offen:
$15.61
24-Stunden-Volumen:
1.34M
Relative Volume:
1.28
Marktkapitalisierung:
$2.13B
Einnahmen:
$283.06M
Nettoeinkommen (Verlust:
$287.20M
KGV:
7.703
EPS:
2.0771
Netto-Cashflow:
$135.69M
1W Leistung:
+14.45%
1M Leistung:
+11.73%
6M Leistung:
+41.34%
1J Leistung:
+104.87%
1-Tages-Spanne:
$15.55
$16.32
1-Wochen-Bereich:
$14.16
$16.32
52-Wochen-Spanne:
$6.825
$16.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.00 | 2.08B | 283.06M | 287.20M | 135.69M | 2.0771 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | Hochstufung | Jefferies | Hold → Buy |
| 2025-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2025 Earnings Call Transcript - MSN
Moving Averages: Is Aurinia Pharmaceuticals Inc part of any major index2026 Retail Activity & Safe Entry Momentum Tips - baoquankhu1.vn
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - TipRanks
Aurinia to Acquire Kezar via $6.955-Per-Share Cash Tender Plus CVR - TradingView
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - stocktitan.net
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - stocktitan.net
How Aurinia Pharmaceuticals Inc (AUPH) Affects Rotational Strategy Timing - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (AUP.TO) Competitors - Meyka
Aurinia Pharmaceuticals (AUPH) COO Ryan Cole becomes SEC Form 3 insider - stocktitan.net
Aurinia Pharmaceuticals (AUPH) CFO Michael Hearne becomes reporting insider with Form 3 - stocktitan.net
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Major Kezar (KZR) shareholder signs merger support pact and drops bid - stocktitan.net
JPMorgan Chase & Co. Grows Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH - marketbeat.com
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
EBIT per share of Aurinia Pharmaceuticals Inc. – LSE:0UJF - TradingView
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - marketscreener.com
Aurinia to acquire Kezar Life Sciences for $6.955 per share By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals Acquires Kezar Life Sciences - Contract Pharma
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal - TipRanks
Kezar Life Sciences stock jumps on Aurinia acquisition deal By Investing.com - Investing.com Australia
Kezar Life Sciences stock jumps on Aurinia acquisition deal - Investing.com
Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR - stocktitan.net
Aurinia to acquire Kezar Life Sciences for $6.955 per share - Investing.com
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
How Aurinia’s Tang-Led C-Suite Overhaul Will Impact Aurinia Pharmaceuticals (AUPH) Investors - Sahm
Does Aurinia’s Tang‑Led Leadership Overhaul Reshape the Bull Case for Aurinia Pharmaceuticals (AUPH)? - finance.yahoo.com
Investors - Aurinia Pharmaceuticals Inc.
Mutiny at Aurinia Pharmaceuticals? Biotech rallies on C-suite shake-up - MSN
AUPH stock rallies after CEO shake-up: Retail bulls bet on turnaround - MSN
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance (NASDAQ:AUPH) - Seeking Alpha
AUPH Should I Buy - Intellectia AI
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH): A High-Growth Momentum and Technical Trend Case Study - ChartMill
AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround - Stocktwits
AURINIA PHARMACEUTICALS PB Ratio: 3.29 — 11% Below Median - GuruFocus
The Escalator: Aurinia Pharmaceuticals, Abivax, Ogilvy Health and more - Medical Marketing and Media
Aurinia Pharmaceuticals (AUPH) stock drops after strong quarter, softer forward revenue targets - MSN
[SCHEDULE 13D/A] Aurinia Pharmaceuticals Inc. Amended Major Shareholder Report - Stock Titan
Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning - Sahm
AUPH SEC FilingsAurinia Pharmace 10-K, 10-Q, 8-K Forms - Stock Titan
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Mar 02 '26 |
Buy |
14.26 |
199,353 |
2,842,833 |
12,045,292 |
| TANG KEVIN | Director |
Mar 03 '26 |
Buy |
14.22 |
184,208 |
2,619,438 |
12,229,500 |
| TANG KEVIN | Director |
Aug 01 '25 |
Buy |
10.12 |
1,000,000 |
10,120,000 |
11,029,500 |
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):